Literature DB >> 8609615

Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactivity.

J Thompson1, T Pope, J S Tung, C Chan, G Hollis, G Mark, K S Johnson.   

Abstract

The present study set out to investigate whether phage display could be used to improve the properties of a high-affinity human monoclonal antibody directed against the third hypervariable loop (V3 loop) of human immunodeficiency virus (HIV). The aim was to increase affinity through slowing the dissociation rate (off-rate constant of koff), whilst retaining the ability of this antibody to bind diverse V3 loop sequences. When reformatted as a scFv, the antibody fragment retained the properties of the parental IgG, including the ability to neutralise virus. Heavy and light chains were sequentially replaced with repertoires of variable domains from non-immunised human donors followed by selection on biotinylated synthetic peptide. All selected variants derived from the same germline as the parental antibody. Variants of the light chain provided little if any improvement, whereas two residue changes in VHCDR2 and one in VHFR3 resulted in a reduced koff from gp120 protein of the MN strain (MNgp120) and synthetic V3 loop peptides as measured by surface plasmon resonance using the BIAcore instrument (Pharmacia Biosensor). VHCDR3 was modified using synthetic oligonucleotides and several clones with reduced koff identified, a number of different substitutions occurring at a single residue position. The residues in the heavy chain identified as reducing koff were simultaneously randomised by site-directed mutagenesis, resulting in scFv variants with koff slowed up to sevenfold. Far from compromising recognition of variant loops, binding to these sequences was improved; the koff from synthetic peptides modelled on V3 loop variants being slowed to a degree similar to that observed with MNgp120. All four changes were located towards either extremes of CDRs 2 and 3, suggesting that the mechanism of improvement may be one of alternation of loop conformation. This work illustrates that phage display can be used to tailor the properties of a therapeutic monoclonal antibody in a predefined fashion.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8609615     DOI: 10.1006/jmbi.1996.0069

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  22 in total

Review 1.  Generation of recombinant antibodies.

Authors:  S M Kipriyanov; M Little
Journal:  Mol Biotechnol       Date:  1999-09       Impact factor: 2.695

Review 2.  Genetic and structural determinants of virus neutralizing antibodies.

Authors:  J E Crowe; R O Suara; S Brock; N Kallewaard; F House; J H Weitkamp
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

Review 3.  Development of anti-infectives using phage display: biological agents against bacteria, viruses, and parasites.

Authors:  Johnny X Huang; Sharon L Bishop-Hurley; Matthew A Cooper
Journal:  Antimicrob Agents Chemother       Date:  2012-06-04       Impact factor: 5.191

4.  A general method for greatly improving the affinity of antibodies by using combinatorial libraries.

Authors:  Arvind Rajpal; Nurten Beyaz; Lauric Haber; Guido Cappuccilli; Helena Yee; Ramesh R Bhatt; Toshihiko Takeuchi; Richard A Lerner; Roberto Crea
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-06       Impact factor: 11.205

5.  Identification by phage display and characterization of two neutralizing chimpanzee monoclonal antibodies to the hepatitis E virus capsid protein.

Authors:  D J Schofield; J Glamann; S U Emerson; R H Purcell
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

6.  Affinity maturation of Cry1Aa toxin to the Bombyx mori cadherin-like receptor by directed evolution.

Authors:  Yuki Fujii; Shiho Tanaka; Manami Otsuki; Yasushi Hoshino; Haruka Endo; Ryoichi Sato
Journal:  Mol Biotechnol       Date:  2013-07       Impact factor: 2.695

7.  Open reading frame mining identifies a TLR4 binding domain in the primary sequence of ECRG4.

Authors:  Xitong Dang; Raul Coimbra; Liang Mao; Sonia Podvin; Xue Li; Hua Yu; Todd W Costantini; Xiaorong Zeng; Dana Larocca; Brian P Eliceiri; Andrew Baird
Journal:  Cell Mol Life Sci       Date:  2019-06-12       Impact factor: 9.261

8.  Identification of a potent anti-IL-15 antibody with opposing mechanisms of action in vitro and in vivo.

Authors:  D K Finch; A Midha; C L Buchanan; D Cochrane; R I Craggs; S Cruwys; C Grahames; R Kolbeck; D C Lowe; J Maltby; D V Pattison; K A Vousden; A Ward; M A Sleeman; P R Mallinder
Journal:  Br J Pharmacol       Date:  2011-01       Impact factor: 8.739

9.  Protein engineering and preclinical development of a GM-CSF receptor antibody for the treatment of rheumatoid arthritis.

Authors:  R R Minter; E S Cohen; B Wang; M Liang; I Vainshtein; G Rees; L Eghobamien; P Harrison; D A Sims; C Matthews; T Wilkinson; P Monk; C Drinkwater; L Fabri; A Nash; M McCourt; L Jermutus; L Roskos; I K Anderson; M A Sleeman
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

10.  A system for the directed evolution of the insecticidal protein from Bacillus thuringiensis.

Authors:  Hiroshi Ishikawa; Yasushi Hoshino; Yutaka Motoki; Takuma Kawahara; Mika Kitajima; Madoka Kitami; Ayako Watanabe; Alejandra Bravo; Mario Soberon; Atsuko Honda; Katsuro Yaoi; Ryoichi Sato
Journal:  Mol Biotechnol       Date:  2007-06       Impact factor: 2.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.